Cingulate Inc Stock Price, News & Analysis

Welcome to our dedicated page for Cingulate news (Ticker: CING), a resource for investors and traders seeking the latest updates and insights on Cingulate stock.

Cingulate Inc. (NASDAQ: CING) generates frequent news as a clinical-stage biopharmaceutical company advancing its Precision Timed Release™ (PTR™) platform and lead ADHD candidate, CTx-1301. This news page aggregates company press releases, analyst coverage, and regulatory updates so readers can follow key developments in Cingulate’s late-stage clinical and regulatory journey.

Recent announcements highlight major milestones for CTx-1301, including submission and FDA acceptance of the New Drug Application under the 505(b)(2) pathway, assignment of a Prescription Drug User Fee Act (PDUFA) target action date, and positive Phase 3 trial results in adult and pediatric ADHD populations. News items also cover presentations of clinical data at scientific meetings, such as podium presentations at the American Academy of Child and Adolescent Psychiatry (AACAP) Annual Meeting.

Investors and followers of CING can use this page to track quarterly financial results, capital-raising transactions, and material agreements disclosed through press releases and referenced in Form 8-K filings. Examples include commercial supply agreements with Bend Bio Sciences, commercialization partnerships with Indegene, and financing arrangements such as promissory notes and equity purchase agreements.

Corporate updates, including executive appointments in commercial leadership and board-level changes, are also reflected in Cingulate’s news flow. Together, these items provide context on how the company is preparing for potential commercialization of CTx-1301 and expanding its PTR-based pipeline in ADHD, anxiety, and other neuropsychiatric indications. Bookmark this page to review new CING headlines, clinical data disclosures, regulatory milestones, and business updates as they are released.